Pfizer Inc. (PFE) announced results from an exploratory analysis of the Intergroup Exemestane Study at a median follow-up of 91 months in estrogen-receptor positive or estrogen-receptor unknown women that looked at breast cancer free survival and censored deaths that occurred prior to breast cancer relapse.
The company stated that the data showed that women who switched to Aromasin after 2.5 years of tamoxifen experienced a 19% reduction in risk of breast cancer recurrence compared to women who continued on tamoxifen for a full five years of treatment.
The company said, results from the Tamoxifen, Exemestane, Adjuvant, Multicenter study did not show a difference in disease free survival in women who took Aromasin for five years compared to those who switched from tamoxifen to Aromasin after two to three years.
The company noted that the data from Intergroup Exemestane Study and Tamoxifen, Exemestane, Adjuvant, Multicenter study continue to underscore the benefits of Aromasin for postmenopausal women with hormone-receptor positive/unknown early breast cancer.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.